{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:54Z","timestamp":1787014134917,"version":"build-2736575974"},"reference-count":66,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The advent of high\u2010dose melphalan with autologous stem\u2010cell transplantation (\n                    <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>\n                    ), the availability of novel agents such as thalidomide, lenalidomide (immunomodulatory drugs or\n                    <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>\n                    iDs) and bortezomib (proteasome inhibitor) and improvements in supportive care have allowed to increase overall survival in multiple myeloma (\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    ) patients; nevertheless,\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    remains an incurable pathology. For this reason, newer agents are required for continued disease control. Bendamustine is an old drug rediscovered in the last decade. In fact, its unique mechanism of action with structural similarities to both alkylating agents and antimetabolities, but which is not cross\u2010resistant to alkylating agents, has reawakened interest in the use of this drug in the treatment of\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    . Studies have proven the safety and efficacy of bendamustine administered alone or in combination with new drugs in both upfront and relapse\/refractory settings of\n                    <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\n                    patients, including those with renal impairment. Moreover, bendamustine has been successfully used as conditioning for autologous stem\u2010cell transplantation. Finally, the use of bendamustine does not compromise peripheral blood stem\u2010cell collection. This drug is generally well tolerated, with the majority of adverse events being due to myelosuppression. Non\u2010haematological adverse events are infrequent and usually mild.\n                  <\/jats:p>","DOI":"10.1111\/ejh.12609","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T04:47:19Z","timestamp":1434602839000},"page":"377-388","source":"Crossref","is-referenced-by-count":27,"title":["Bendamustine in multiple myeloma"],"prefix":"10.1111","volume":"95","author":[{"given":"Massimo","family":"Gentile","sequence":"first","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Grazia","family":"Recchia","sequence":"additional","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Morabito","sequence":"additional","affiliation":[{"name":"Medical Oncology &amp; Hematology Unit Humanitas Cancer Center Istituto Clinico Humanitas IRCCS Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Giagnuolo","sequence":"additional","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Haematology Unit Department of Onco\u2010Haematology A.O. of Cosenza Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_12_5_1","unstructured":"National Cancer Institute.Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma.2013.http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html(accessed April 24 2013)"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0100"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1925"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0229"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12097"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7252"},{"key":"e_1_2_12_16_1","first-page":"1013","article-title":"IMET3393 ([1methyl\u20105\u2010bis\u2010(b\u2010chloroethyl)\u2010 aminobenz\u2010imidazolyl\u2010(2)]\u2010butyric acid hydrochloride, a new cytotoxic agent from among the series of benzimidazole mustard compounds [in German]","volume":"110","author":"Ozegowski W","year":"1971","journal-title":"Zbl Pharm"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01633.x"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0388"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1317-x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(72)90282-1"},{"key":"e_1_2_12_22_1","first-page":"1267","article-title":"UntersuchungenzurPlasmaeiweissbindung von Bendamustine(Cytostasan) und Ambazon","volume":"45","author":"Haase D","year":"1990","journal-title":"Z Klein Med"},{"key":"e_1_2_12_23_1","first-page":"782","article-title":"The pharmacokinetics of bendamustine (Cytostasan) in humans","volume":"40","author":"Preiss R","year":"1985","journal-title":"Pharmazie"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.015958"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34872"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022855"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0378-6"},{"key":"e_1_2_12_29_1","unstructured":"Cephalon Inc.Treanda\u00ae[prescribing information] Bendamustine hydrochloride for injection for intravenous infusion. Cephalon Inc: Frazer (PA) 2009 April.http:\/\/www.treanda.com\/300-nhl-home.aspx."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090328"},{"key":"e_1_2_12_31_1","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high\u2010dose chemotherapy","volume":"90","author":"Knop S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-15-1-13"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.622422"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08887.x"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07076.x"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2238-2"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13435"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395715"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12361"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V122.21.3212.3212","article-title":"Bendamustine, low\u2010dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed multiple myeloma confirms very promising results in a phase I\/II study","volume":"122","author":"Pozzi S","year":"2013","journal-title":"Blood"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1182\/blood.V124.21.4779.4779","article-title":"Multicenter phase II trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) as 2nd\u2010line therapy for multiple myeloma","volume":"124","author":"Mey U","year":"2014","journal-title":"Blood"},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood.V112.11.5171.5171","article-title":"Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cell","volume":"112","author":"Zhang S","year":"2008","journal-title":"Blood"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1182\/blood.V110.11.4851.4851","article-title":"Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. Clinical observation","volume":"110","author":"Hrusovsky I","year":"2007","journal-title":"Blood"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701694194"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12129"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-012-1339-3"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.58"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1182\/blood.V124.21.4734.4734","article-title":"Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapsed\u2010refractory multiple myeloma (MM): updated results of a multicenter phase II study","volume":"124","author":"Offidani M","year":"2014","journal-title":"Blood"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-521468"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.110890"},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/blood.V120.21.4035.4035","article-title":"Preliminary experience of the Spanish compassionate use registry of bendamustine in patients with relapsed and\/or refractory multiple myeloma","volume":"120","author":"AguadoBueno B","year":"2012","journal-title":"Blood"},{"key":"e_1_2_12_52_1","first-page":"1","article-title":"Bendamustine in relapsed\/refractory multiple myeloma: the \u201creal\u2010life\u201d side of the moon","volume":"3","author":"Musto P","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124818"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1737-9"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-012-1212-4"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-013-1513-2"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08754.x"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood.V118.21.1933.1933","article-title":"Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma","volume":"118","author":"P\u00f6nisch W","year":"2011","journal-title":"Blood"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1984-4"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.02.013"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2516.2516"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2199"},{"key":"e_1_2_12_67_1","unstructured":"Napp Pharmaceuticals Limited.Levact 2.5\u00a0mg\/ml powder for concentrate for solution for infusion. Summary of product characteristics[online].www.medicines.org.uk\/emc\/medicine\/23469."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12609","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:15:04Z","timestamp":1696338904000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/ejh.12609"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12609","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}